middle.news
Starpharma Secures FDA Alignment for DEP® HER2 Phase 1 Trial
10:42am on Wednesday 29th of April, 2026 AEST
•
Biotechnology
Read Story
Starpharma Secures FDA Alignment for DEP® HER2 Phase 1 Trial
10:42am on Wednesday 29th of April, 2026 AEST
Key Points
FDA confirms DEP® HER2 phase 1 clinical plan
Strategic partnerships advance with Genentech data published
Viraleze™ sales up 65% year-to-date
Quarter-end cash balance of $14.1 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE